<DOC>
	<DOCNO>NCT00108953</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy doxorubicin plus sorafenib versus doxorubicin plus placebo patient advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Research Study Treat Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>In addition key secondary outcome parameter follow parameter assess exploratory manner : relative time progression ( TTP ) , time symptomatic progression ( TTSP ) , response rate ( RR ) overall survival 2 study population . The possible potential predictive assay clinical benefit assessment correlation define baseline characteristic key clinical endpoint . The safety tolerability assess adverse event section . Doxorubicin pharmacokinetics HCC patient treat sorafenib versus placebo compare pharmacokinetic data correlate doxorubicin-related adverse event ( i.e. , cardiotoxicity ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients life expectancy least 12 week Patients advanced HCC ( unresectable , and/or metastatic ) histologically cytologically documented Patients must least one tumor lesion meet follow criterion : accurately measure least one dimension accord Response Evaluation Criteria Solid Tumors ( RECIST ) previously treat local therapy Patients receive local therapy except chemoembolization , surgery , radiation therapy , hepatic arterial embolization , radiofrequency ablation , percutaneous ethanol injection cryoablation eligible , provide either target lesion subject local therapy and/or target lesion ( ) within field local therapy show increase 25 % size . Local therapy must complete least 4 week prior baseline scan Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permitted History cardiac disease Serious myocardial dysfunction Active , clinically serious infection Known history Human Immunodeficiency Virus ( HIV ) infection Known Central Nervous System ( CNS ) tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
</DOC>